Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $5.00

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given an average recommendation of “Hold” by the six analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $5.00.

Separately, Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target on the stock.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $2.62 on Thursday. The firm has a market cap of $189.30 million, a price-to-earnings ratio of -1.27 and a beta of 1.71. The firm has a fifty day moving average price of $2.65 and a 200 day moving average price of $1.92. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $3.95.

Insider Activity

In related news, insider Vincent Vultaggio sold 29,951 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $2.43, for a total value of $72,780.93. Following the sale, the insider directly owned 156,779 shares in the company, valued at approximately $380,972.97. The trade was a 16.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Group Walters purchased 6,459,973 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The shares were purchased at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the completion of the purchase, the insider owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. The trade was a 91.63% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 46,617 shares of company stock worth $113,417 over the last ninety days. Insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC increased its position in Zentalis Pharmaceuticals by 177.6% in the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after purchasing an additional 396,233 shares during the last quarter. Millennium Management LLC lifted its position in Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Savant Capital LLC bought a new position in Zentalis Pharmaceuticals during the second quarter valued at $59,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth $31,000. Finally, XTX Topco Ltd grew its stake in shares of Zentalis Pharmaceuticals by 112.9% in the 2nd quarter. XTX Topco Ltd now owns 264,829 shares of the company’s stock worth $307,000 after buying an additional 140,433 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.